Showing results (51-60 of 60) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Blood|May 31, 2002
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trialGregory A Wiseman, Leo I Gordon, Pratik S Multani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomographyMalik E Juweid, Gregory A Wiseman, Julie M Vose, et al.Cancer Immunity|August 21, 2007
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinomaIan D Davis, Gregory A Wiseman, Fook-Thean Lee, et al.British Journal of Haematology|May 4, 2017
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphomaNarendranath Epperla, Anthony Q Pham, Brian L Burnette, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2007
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaMalik E Juweid, Sigrid Stroobants, Otto S Hoekstra, et al.American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.Leukemia & Lymphoma|November 12, 2025
Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141)Robert Jeraj, Fenghai Duan, Ryan J Mattison, et al.American Journal of Hematology|April 27, 2013
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphomaThomas E Witzig, Gregory A Wiseman, Matthew J Maurer, et al.Cardiovascular and Interventional Radiology|October 25, 2012
Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinomaLaura E Moreno-Luna, Ju Dong Yang, William Sanchez, et al.Blood|April 21, 2017
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLLWei Ding, Betsy R LaPlant, Timothy G Call, et al.Pageof 6